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ABSTRACT
A major impediment to the response of tumors to chemotherapy is that the large 
majority of cancer cells within a tumor are quiescent in G0/G1, where cancer cells 
are resistant to chemotherapy.  To attempt to solve this problem of quiescent cells 
in a tumor, cancer cells were treated with recombinant methioninase (rMETase), 
which selectively traps cancer cells in S/G2. The cell cycle phase of the cancer cells 
was visualized with the fluorescence ubiquitination cell cycle indicator (FUCCI).  At 
the time of rMETase-induced S/G2-phase blockage, identified by the cancer cells’ 
green fluorescence by FUCCI imaging, the cancer cells were administered S/G2-
dependent chemotherapy drugs, which interact with DNA or block DNA synthesis 
such as doxorubicin, cisplatin, or 5-fluorouracil. Treatment of cancer cells with 
drugs only, without rMETase-induced S/G2 phase blockage, led to the majority of the 
cancer-cell population being blocked in G0/G1 phase, identified by the cancer cells 
becoming red fluorescent in the FUCCI system.  The G0/G1 blocked cells were resistant 
to the chemotherapy.  In contrast, trapping of cancer cells in S/G2 phase by rMETase 
treatment followed by FUCCI-imaging-guided chemotherapy was highly effective in 
killing the cancer cells.
INTRODUCTION
The problem of quiescent cancer cells within a 
tumor
The resistance of most solid tumors and metastases 
is a major problem in chemotherapy. The phase of the cell 
cycle determines to a great extent whether a cancer cell 
can respond to a given drug. We previously monitored 
real-time cell cycle dynamics of cancer cells throughout a 
live tumor intravitally using a fluorescence ubiquitination 
cell cycle indicator (FUCCI). Approximately 90% 
of cancer cells in the center and 80% of total cells of 
an established tumor are in G0/G1 phase. Similarly, 
approximately 75% of cancer cells far from (> 100 µm) 
tumor blood vessels of an established tumor are in G0/G1. 
FUCCI imaging demonstrated that cytotoxic agents killed 
only proliferating cancer cells at the surface, or near blood 
vessels, and had little effect on the majority of quiescent 
cancer cells within a tumor. Resistant quiescent cancer 
cells restarted cycling after the cessation of chemotherapy. 
Thus, the low chemo-sensitivity of most solid tumors is 
at least in part due to the large majority of cancer cells in 
solid tumors being quiescent [1]. 
FUCCI imaging was used for real-time visualization 
of the cell cycle kinetics of invading cancer cells in 
3-dimensional (3D) Gelfoam® histoculture. Cancer 
cells in G0/G1 phase in Gelfoam® histoculture migrated 
more rapidly and further than the cancer cells in S/G2/M 
phase. After entry into S/G2/M phases, cancer cells ceased 
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migrating and restarted migrating after division when 
the cells re-entered G0/G1. Migrating cancer cells were 
resistant to cytotoxic chemotherapy, since they were 
mostly in G0/G1 [2]. 
One solution to the problem of large numbers of 
cells in G0/G1 in a tumor is to block the cancer cells in S/
G2 rather than G0/G1.
Methionine dependence
Methionine dependence, the elevated methionine 
requirement for cancer cell proliferation, is the property 
of the majority of cancer cell types [3]. There have been 
several therapeutic strategies to target the methionine 
dependence of cancer cells. Methionine-starvation therapy, 
such as with a methionine-free diet or methionine-depleted 
total parenteral nutrition, prolonged the survival time 
of tumor-bearing rodents [4, 5]. Methionine-free total 
parenteral nutrition in combination with chemotherapeutic 
drugs extended the survival of patients with high-stage 
gastric cancer [4]. Prostate-cancer patients have been 
treated with a methionine-depleted diet [5]. 
A reversible growth arrest of cancer cells has 
been produced by replacement of methionine in the 
growth medium by its immediate metabolic precursor, 
homocysteine, This growth arrest is accompanied by 
a reduction in the percentage of mitotic cells in the cell 
population. Furthermore, fluorescence-activated cell 
sorting demonstrated that the cells are arrested at the S/
G2 phase of the cell cycle. This is in contrast to a G1-
phase accumulation of cancer cells, which occurs only in 
methionine-supplemented medium at very high densities 
and which is similar to the G1 block seen in cultures of 
normal fibroblasts at high density [6]. The molecular 
mechanism of the S/G2 block has subsequently been 
investigated [7]. 
The S/G2 trap that that cancer cells enter upon 
methionine starvation was exploited for selective 
chemotherapy in vitro. In cultures that were initiated 
with equal amounts of cancer cells and human diploid 
fibroblasts, substitution of homocysteine and doxorubicin 
for methionine in the culture medium followed by 
methionine repletion with vincristine was totally effective 
at selectively eliminating a methionine-dependent 
human sarcoma and three methionine-dependent human 
carcinomas. This chemotherapeutic procedure used was 
not toxic to normal cells growing alongside the cancer 
cells and was ineffective when conducted totally in 
methionine-containing medium [8].
In the present report, we demonstrate that using 
recombinant methioninase (rMETase) to deplete 
methionine and thereby trap cancer cells in S/G2, 
and FUCCI imaging to detect the onset of the block, 
chemotherapy could become effective on the S/G2-trapped 
cancer cells.
RESULTS AND DISCUSSION
Recombinant methionine (rMETase) block of 
cancer cells in S/G2 visualized by FUCCI imaging
After seeding on 35 mm glass dishes and culture 
over night, HeLa cells were treated with rMETase at a 
dose of 1.0 unit/ml. rMETase blocked HeLa and MCF-7 
cells in the S/G2 phase of the cell cycle as visualized by 
FUCCI imaging (Figure 1).
After seeding on 35 mm glass dishes and culture 
over night, HeLa and MCF-7 cells were treated with 
rMETase either at 0.25 or 0.5 units/ml for 48 hours. 
FUCCI imaging showed that by 24 hours there was a large 
shift in the cancer-cell population from G0/G1 to S/G2/M 
(Figure 2). For HeLa cells, the percentage of cells in G0/G1 
decreased from approximately 80% to approximately 20% 
Figure 1:  Time-lapse imaging of FUCCI-expressing HeLa cells treated with rMETase. After seeding on 35 mm glass dishes 
and culture over night, HeLa cells were treated with rMETase at a dose of 1.0 unit/ml. All images were acquired with the FV1000 confocal 
microscope (Olympus, Tokyo, Japan). The cells in G0/G1, S, or G2/M phases appear red, yellow, or green, respectively. Scale bar: 50 μm.
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by 48 hours in the presence of either 0.25 or 0.5 units/ml 
rMETase. Approximately 80% of the population became 
blocked in S/G2. For MCF-7 cells, approximately 40% of 
the untreated cells were in G0/G1. After 48 hours treatment 
with 0.25 units/ml rMETase, the percentage of cells in G0/
G1 fell to 20% and with 0.5 units rMETase, the percentage 
decreased to approximately 15%. Approximately 85% of 
the cells became trapped in S/G2 (Figure 2).
Cytotoxic chemotherapy drugs killed cancer cells 
trapped in S/G2 by rMETase
During rMETase-induced blockage in S/G2, 
doxorubicin (DOX) effectively killed the cancer cells. 
After overnight culture, HeLa cells and MCF-7 cells 
were treated with 0.25 unit/ml rMETase for 48 hours. 
The cancer cells were then treated with 0.5 μg/ml DOX 
(HeLa cells) or 2.5 μg/ml DOX (MCF-7) for 72 hours. 
HeLa cells were also treated with 0.5 μg/ml DOX, and 
MCF-7 cells were treated with 2.5 μg/ml DOX for 72 
hours, both without rMETase. With HeLa cells, DOX 
treatment alone resulted in an increase of cells in G0/
G1 from approximately 60% to 80%. With combination 
treatment of DOX and rMETase, the number of HeLa cells 
in G0/G1 was reduced to approximately 0 with almost all 
cells blocked in S/G2. For MCF-7 cells, approximately 
40% of the untreated cells were in G0/G1 and increased 
to more than 80% after treatment with DOX alone for 72 
hours. In the presence of rMETase and DOX for 72 hours, 
approximately 40% of the cells were in G0/G1 (Figure 3).
DOX alone, at 2.5 µg/ml, killed approximately 25% 
of the MCF-7 cells. The combination of DOX, at 2.5 µg/
ml, and rMETase, at 0.25 units/ml, killed approximately 
80% of the cells (P<0.01 compared to DOX alone). 
DOX, at 5 µ/ml, and rMETase, at 0.25 units/ml, killed 
approximately 90% of the cells (P<0.01 compared to 
DOX alone) (Figure 4).
For MCF-7 cells treated with 5-FU, at 15 µg/
ml, approximately 40% of the cells were killed. With 
the combination of rMETase (0.25 units/ml) and 15 µg/
ml 5-FU, approximately 80% of the cells were killed 
(P<0.01 compared to 5-FU alone). With 5-FU, at 30 µg/
ml, approximately 40% of the cells were killed, and the 
combination of 5-FU, at 30 µg/ml, and 0.25 units/ml 
rMETase, approximately 90% of the cells were killed 
Figure 2:  rMETase traps cancer cells in S/G2 phase.  After seeding on 35 mm glass dishes and culture over night, HeLa cells 
and MCF-7 cells were treated with rMETase, at the indicated doses, for 48 hours. a. Representative images of control or rMETase-treated 
cells. b. Histogram shows the percentages of cells in G1 (red), early S (yellow), or late S/G2/M (green). Cells at each cell cycle phase were 
quantitatively assessed by counting the number of cells with each color.  N=5 experiments were analyzed. Scale bars: 50 μm. 
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(P<0.01 compared to 5-FU alone) (Figure 4).
The strategy and technology described in this report, 
whereby cancer cells are selectively and synchronously 
trapped by rMETase in S/G2, the most drug-sensitive phase 
of the cell cycle, where they were identified by FUCCI 
imaging and then treated with S/G2-phase-specific-drugs 
was highly effective compared to standard chemotherapy.
Previously developed concepts and strategies of 
highly selective tumor-targeting [9-20] can take advantage 
of spatial–temporal cell-cycle imaging of cancer cells 
described in the present and previous [1, 2, 21] reports. 
Previously, different methods of cancer-cell 
synchronization have been used in order to sensitize 
the cells to chemotherapy. Such methods include 
Figure 4:  Chemotherapy of S/G2-trapped cancer cells. Efficacy of combination therapy of rMETase and 5-FU (a); rMETase and 
DOX (b); on FUCCI-expressing MCF-7 cells. Cell viability was assessed by counting living cells compared to control. Data bars means ± 
SD of triplicate samples.
Figure 3:  FUCCI cell cycle analysis during chemotherapy with and without rMETase. After overnight culture, HeLa 
cells (a, b and c) and MCF-7 cells (d, e and f) were treated with 0.25 unit/ml rMETase for 48 hours and, then were treated with 0.5 μg/ml 
doxorubicin (HeLa cells) or 2.5 μg/ml doxorubicin (MCF-7) for 72 hours. For conventional chemotherapy, after culture for 48 hours, HeLa 
cells (a, b and c) and MCF-7 cells (d, e and f) were treated with 0.5 μg/ml DOX (HeLa cells) or 2.5 μg/ml DOX (MCF-7) for 72 hours. a, b, 
d, e Representative images acquired with the FV-1000 are shown. c, f, Histograms show the percentages of cells G1(red), early-S (yellow), 
or late-S/G2/M (green). Cells at each cell cycle phase were quantitatively assessed by counting the number of cells with each color.  N=5 
experiments were analyzed. Scale bars: 50 μm. 
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chronotherapy which attempts to target the time of day 
when most cancer cells in tumors are thought to be 
dividing [22]. Excess thymidine or its analogs have also 
been used to arrest cancer cells in S-phase, where they are 
sensitized to S-phase drugs such as 5-FU or methotrexate, 
and after release of the block, the cancer cells enter 
M-phase synchronously where they are sensitive to 
M-Phase drugs such as paclitaxel [23-25]. 
Cancer-cell synchronization with cell-cycle-phase-
specific drugs, such as cytosine arabinoside, methotrexate 
and hydroxyorea have also been carried out [26-30], for 
example, to block cells in S-phase which can sensitize 
the cancer cells to an M-phase drug, such as paclitaxel, 
administered after the S-phase block is lifted [26-30]. 
The calcium channel blocker mibefradil has 
been used to synchronize glioblastoma cells at the G1/S 
checkpoint, thereby making the glioblastoma cells 
sensitive to first-line therapy temozolomide [31]. Statins, 
such as Lovastatin, can be used to synchronize cancer in 
G1 by preventing formation of an early intermediate in 
the cholesterol pathway essential for progression of cells 
through early G1 phase [32, 33]. After the block is lifted, 
the cancer cells can be effectively treated with an S-phase 
drug.
PDO332991, a pyridopyrimidine, has been shown to 
be a selective inhibitor of cyclin-dependent kinases 4 and 
6 and induced early-G1 arrest in primary human myeloma 
cells and other cancer cell types, including breast cancer 
in vitro and in cancer xenograft models. As PDO0332991 
acts reversibly, it can be used as a synchronizing agent and 
when used for sequence combination with cytotoxic agents 
is active against myeloma cells in vitro and in vivo [34]. 
A cyclin-dependent kinase inhibitor RO-3306 reversibly 
arrests 95% of treated cells in G2 phase. These cells 
rapidly enter mitosis after the block is lifted and become 
sensitive to M-phase drugs [35]. Growth factors such as 
EGF, G-CSF, and IL-6 can stimulate cancer cell out of 
G0, making them sensitive to chemotherapy agents such 
as docetaxel [36-38]. Reviews on cell synchronization are 
available [39-42]. 
The critical advantage of rMETase synchronization 
(blockage) is that, unlike the methods described above, it 
is cancer specific [3,6,8,43-51].
CONCLUSIONS
A major problem for successful chemotherapy is the 
very high percentage of quiescent G0/G1 cancer cells in 
a tumor. The present report has demonstrated a solution 
to the problem by selectively trapping cancer cells in S/
G2, with recombinant methioninase (rMETase). The S/G2-
trapped cancer cells became sensitive to chemotherapy 
which targets cells in this phase of the cell cycle, which 
are the majority of the most widely-used chemotherapy 
drugs. Alternatively, the rMETase-induced S/G2 block can 
be lifted and the cells can become sensitive to M-phase 
drugs. This approach has significant clinical potential 
since almost all cancer cell types tested are methionine 
dependent and arrest in S/G2 when deprived of methionine 
with an agent such as rMETase. 
MATERIALS AND METHODS
Recombinant Methioninase (rMETase)
Recombinant L-methionine α-deamino-γ-
mercaptomethane lyase (methioninase, METase) [EC 
4.4.1.11] from Pseudomonas putida has been previously 
cloned and was produced in Escherichia coli (AntiCancer, 
Inc., San Diego, CA). rMETase is a homotetrameric PLP 
enzyme of 172-kDa molecular mass [52].
FUCCI (Fluorescence ubiquitination cell cycle 
indicator)
The FUCCI probe was generated by fusing mKO2 
(monomeric Kusabira Orange2) and mAG (monomeric 
Azami Green) to the ubiquitination domains of human 
Cdt1 and geminin, respectively. These two chimeric 
proteins, mKO2-hCdt1(30/120) and mAG-hGem(1/110), 
accumulate reciprocally in the nuclei of transfected cells 
during the cell cycle, labeling the nuclei of G1 phase cells 
red and nuclei of cells in S/G2 phase green [53]. 
FUCCI-expressing HeLa cells and MCF-7 cells
Plasmids expressing mKO2-hCdt1 or mAG-hGem 
(MBL, Nagoya, Japan) were transfected into HeLa cells 
and MCF-7 cells. HeLa cells were grown in DMEM 
supplemented with 10% fetal bovine serum and penicillin/
streptomycin. MCF-7 were grown in MEM-supplemented 
with L-glutamine and 10% fetal bovine serum and 
penicillin/streptomycin [53].
Imaging of FUCCI-expressing cancer cells
Time-lapse images of HeLa and MCF-7 cells stably 
transfected with FUCCI vectors were acquired using a 
confocal laser scanning microscope (FV1000; Olympus, 
Tokyo, Japan) [1, 2, 21]. 
Cell viability
For cell viability determinations before and after 
chemotherapy, with and without rMETase, the cells were 
stained with crystal violet, and the relative number of cells 
was quantified using ImageJ (NIH, Bethesda, MD). 
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